Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2017
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysisLiat Vidal, Anat Gafter-Gvili, Gilles Salles, et al.
Cancers|June 21, 2020
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung CancerMark Kriegsmann, Christian Haag, Cleo-Aron Weis, et al.
Lancet (London, England)|December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 studyMartin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Nature Genetics|March 19, 2013
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaNiels Weinhold, David C Johnson, Daniel Chubb, et al.
Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.
Pageof 8